Ziopharm Oncology (ZIOP +1.8%) trades higher after intitiating Phase 2 clinical studies of...

|By:, SA News Editor

Ziopharm Oncology (ZIOP +1.8%) trades higher after intitiating Phase 2 clinical studies of Ad-RTS IL-12 in combination with palifosfamide to treat patients with non-resectable recurrent or metastatic breast cancer.